The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer

Xuelu Li1 Department of Breast Surgery

Chen Song2 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

Gena Huang2 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

Siwen Sun2 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

Jingjing Qiao2 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

Jinbo Zhao2 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

Zuowei Zhao1 Department of Breast Surgery

Man Li2 Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of ChinaCorrespondence[email protected]

show all

Abstract

This article has been retracted.

Li X, Song C, Huang G, Sun S, Qiao J, Zhao J, Zhao Z, Li M. The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer. OncoTargets and Therapy. 2017;10:1735–1742.

The authors have advised us of concerns about the specificity of the primary antibody which have resulted in misleading and false results.

View retraction statement:

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction]

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer

Information for

Open access

Opportunities

Help and information

The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer

Abstract

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature